Business
IQVIA provides clinical research, healthcare data, analytics and technology services.
IQVIA: Revenue grew 5.9% to $16.31B from $15.405B. Net income declined 0.9% to $1.36B from $1.373B. Free cash flow declined 3.0% to $2.051B from $2.114B. Operating margin contracted 91 bps to 13.38%. IQVIA's annual comparison also shows free cash flow declined despite revenue growth; stock compensation grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 5.9%OK
- Profitability — Net income declined 0.9% to $1.36B from $1.373BWatch
- Cash flow — Free cash flow declined 3.0% to $2.051B from $2.114BWatch
- Margins — Operating margin contracted 91 bps to 13.38%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 3 salesNote
Where the revenue comes from
Fiscal 2025, as IQVIA HOLDINGS INC. reports it. History and quarterly detail are in the app.
- Research & Development Solutions$8.9B
- Technology & Analytics Solutions$6.6B
- Contract Sales & Medical Solutions$788.0M
Leadership changes
From IQVIA HOLDINGS INC.'s own filings, the day they're filed.
- Michael J. Fedock · President · appointmenteff. 2026-02-28
- Ronald E. Bruehlman · President · appointmenteff. 2026-02-28
- Costa Panagos · President · departureeff. 2023-09-24
Latest filings
- 8-K · Company announcement2026-07-28
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about IQVIA HOLDINGS INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.